Biomea Fusion, Inc.

Contributing Author

Recent Articles by Biomea Fusion, Inc.

12 hours	Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes BMEA +16.06% GlobeNewswire
Aug-13	Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity BMEA GlobeNewswire
Aug-05	Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights BMEA GlobeNewswire
Jun-05	Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ("ADA") 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study BMEA -7.30% BMEA -9.45% GlobeNewswire
Jun-03	Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity BMEA -5.11% GlobeNewswire
May-12	Biomea Fusion to Participate at Upcoming Investor Conferences BMEA BMEA -6.33% GlobeNewswire
May-11	Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights BMEA GlobeNewswire
May-05	Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions BMEA BMEA +5.26% GlobeNewswire
Apr-27	Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment BMEA -8.47% BMEA -11.56% GlobeNewswire
Mar-31	Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies BMEA +15.91% GlobeNewswire
Mar-24	Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights BMEA BMEA +7.96% GlobeNewswire
Mar-14	Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 BMEA GlobeNewswire
Feb-19	Biomea Fusion to Participate at Upcoming Investor Conferences BMEA GlobeNewswire
Jan-12	Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones BMEA GlobeNewswire
Dec-17	Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference BMEA GlobeNewswire
Dec-09	Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 BMEA BMEA +14.93% GlobeNewswire
Dec-05	Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) BMEA GlobeNewswire
Dec-01	Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) BMEA -7.34% BMEA -5.22% GlobeNewswire
Dec-01	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BMEA -7.34% BMEA -5.22% GlobeNewswire
Nov-24	Biomea Fusion to Participate at Upcoming Investor Conferences BMEA GlobeNewswire
Nov-10	Biomea Fusion to Participate at Jefferies London Healthcare Conference BMEA GlobeNewswire
Nov-05	Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek 2025 BMEA +6.35% GlobeNewswire
Nov-04	Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights BMEA GlobeNewswire
Oct-30	Biomea Fusion to Present Poster Presentations at ObesityWeek2025 BMEA GlobeNewswire
Oct-27	Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist BMEA GlobeNewswire
Oct-21	Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series BMEA BMEA -9.43% GlobeNewswire
Oct-07	Biomea Fusion Announces Pricing of Public Offering of Securities BMEA -30.90% GlobeNewswire
Oct-06	Biomea Fusion Announces Proposed Public Offering of Securities BMEA +24.19% GlobeNewswire
Oct-06	Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations BMEA +24.19% BMEA -30.90% GlobeNewswire
Oct-01	Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BMEA GlobeNewswire
Sep-16	Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update BMEA GlobeNewswire
Aug-05	Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights BMEA GlobeNewswire
Jul-24	Biomea Fusion Appoints Julianne Averill to its Board of Directors BMEA GlobeNewswire
Jun-23	Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA) BMEA -6.63% GlobeNewswire
Jun-18	Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates BMEA -34.14% GlobeNewswire
Jun-17	Biomea Fusion Announces Pricing of Public Offering of Securities BMEA -34.14% GlobeNewswire
Jun-17	Biomea Fusion Announces Proposed Public Offering of Securities BMEA +10.27% BMEA -34.14% GlobeNewswire
Jun-13	Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025 BMEA -9.58% GlobeNewswire
May-14	Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia BMEA -10.43% GlobeNewswire
May-05	Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights BMEA -8.26% BMEA -16.50% GlobeNewswire

Biomea Fusion, Inc.

Recent Articles by Biomea Fusion, Inc.

Upgrade your Finviz experience